All In Biotech

Drug Trial Radar · NCT01616654

Dose Range Study of CD5789 in Acne Vulgaris

A Randomized, Multi-center, Investigator-blind, Vehicle- and Active-controlled, Phase 2 Study to Assess the Efficacy and Safety of Different Concentrations of CD5789 Cream Applied Once Daily in Subjects With Moderate to Severe Acne Vulgaris

Last checked: Nov 19, 2026Latest source record: Sep 20, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 304 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

304

Actual

Start

Jun 20, 2012

Primary completion

Jul 24, 2013

Study completion Jun 12, 2014

Sponsor

Lead sponsor
Galderma R&DIndustry
Sponsor type
Industry
First posted
Jun 12, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 12 years, up to 35 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess the efficacy and safety of different concentrations of CD5789 cream in participants with acne vulgaris for the purpose of dose identification.

Conditions

  • Acne Vulgaris

Interventions

  • CD5789 25 µg/g creamDrug

    CD5789 25 µg/g cream applied once daily

  • CD5789 50 µg/g creamDrug

    CD5789 50 µg/g cream applied once daily

  • CD5789 100 µg/g creamDrug

    CD5789 100 µg/g cream applied once daily

  • Tazarotene 0.1% gelDrug

    Tazarotene 0.1% gel applied once daily

  • Vehicle creamDrug

    Vehicle cream applied once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants With Success Rate 1 (SR1)Time frame: From Baseline at Week 12
  2. Absolute Change From Baseline in Total Lesion Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)Time frame: Baseline, Week 12
  3. Percentage Change From Baseline in Total Lesion Counts at Week 12 Using Last Observation Carried Forward (LOCF)Time frame: Baseline, Week 12

Locations

24 sites in 1 country. Site status is shown where the registry gives one.

  • Total Skin and Beauty Dermatology Center, PC

    Birmingham, Alabama

  • Parexel Early Phase

    Glendale, California

  • Odyssey Medispa

    Marina del Rey, California

  • Rady Children's Hospital

    San Diego, California

  • FXM Research Corp Miami

    Miami, Florida

  • FMX Research Miramar

    Miramar, Florida

  • Meda Phase, Inc

    Newnan, Georgia

  • Deaconess Clinic, Inc.

    Evansville, Indiana

  • Dermatology Specialists PC

    Louisville, Kentucky

  • Hamzavi Dermatology

    Fort Gratiot, Michigan

  • Somerset Skin Centre

    Troy, Michigan

  • Skin Specialists, PC

    Omaha, Nebraska

  • Academic Dermatology Associates

    Albuquerque, New Mexico

  • Zoe Drealos, MD

    High Point, North Carolina

  • PMG Research of Wilmington

    Wilmington, North Carolina

  • Central Sooner Research

    Norman, Oklahoma

  • Oregon Dermatology and Research Center

    Portland, Oregon

  • Palmetto Clinical Trial Services, LLC

    Greenville, South Carolina

  • Arlington Center for Dermatology

    Arlington, Texas

  • Suzanne Bruce and Associates P.A. The Center for Skin Research

    Houston, Texas

  • Stephen Miller MD

    San Antonio, Texas

  • Center for Clinical Studies

    Webster, Texas

  • Dermatology Research Center

    Salt Lake City, Utah

  • The Education & Research Foundation, Inc.

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.